Article thumbnail

Comparison of the Safety and Pharmacokinetics of ST-246® after IV Infusion or Oral Administration in Mice, Rabbits and Monkeys

By Yali Chen, Adams Amantana, Shanthakumar R. Tyavanagimatt, Daniela Zima, X. Steven Yan, Gopi Kasi, Morgan Weeks, Melialani A. Stone, William C. Weimers, Peter Samuel, Ying Tan, Kevin F. Jones, Daniel R. Lee, Shirley S. Kickner, Bradley M. Saville, Martin Lauzon, Alan McIntyre, Kady M. Honeychurch, Robert Jordan, Dennis E. Hruby and Janet M. Leeds
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3156126
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2001). A case of human orf in an immunocompromised patient treated successfully with cidofovir cream.
  2. (2007). A Tame Virus Runs Amok.
  3. (2007). Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures.
  4. (2005). An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
  5. (2010). Development of ST246H for Treatment of Poxvirus Infections.
  6. (2009). Disease Control and Prevention (CDC)
  7. (2003). Effectiveness of postexposure vaccination for the prevention of smallpox: results of a delphi analysis.’’
  8. (2007). Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.’’
  9. (2003). Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice.’’
  10. (2007). Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection.’’
  11. (2003). Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney.’’
  12. (2008). Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model.’’
  13. (2005). Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo,
  14. (2009). Global immunization: status, progress, challenges and future.
  15. (2007). Human monkeypox: an emerging zoonotic disease.’’
  16. (2007). In vivo imaging of cidofovir treatment of cowpox virus infection.’’
  17. (1997). Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial.
  18. (2007). N(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors.
  19. (2009). Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
  20. (2001). of Health and Human Services, Food and Drug Administration,
  21. (2001). Outbreak of human monkeypox, Democratic Republic of Congo,
  22. (2003). Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections.’’
  23. (2008). Progress in the discovery of compounds inhibiting orthopoxviruses in animal models.
  24. (1998). Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with
  25. (2010). Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
  26. (2008). Serine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activity.
  27. (2008). Severe Eczema Vaccinatum in a Household Contact of a Smallpox Vaccinee.
  28. (2008). Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
  29. (2009). ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
  30. (2000). Stavrianeas NG. ‘‘Lack of reactivation of cytomegalovirus retinitis in an AIDS patient, during and after stopping long-term cidofovir treatment: case report.’’
  31. (2010). Tecovirimat for smallpox infections.
  32. (2003). Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives.’’
  33. (2003). Treatment of orf poxvirus lesion with cidofovir cream.’’
  34. (2009). Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis.’’
  35. (2007). Viremia in human Cowpox virus infection.